Tickers

1. Composite Trajectory Verdict

For a pre-revenue, clinical-stage biotechnology company, the cash flow statement and balance sheet (liquidity and runway) carry the most weight because the business model depends entirely on external financing to fund operations until potential product approval, which is years away and uncertain.

Composite Trajectory: Mixed

The earnings trajectory shows improvement: quarterly and year-to-date net losses narrowed significantly in 2026 versus 2025 (Q2 net loss $30.4M vs $37.0M; YTD net loss $59.0M vs $71.1M) due to restructuring-driven expense reductions. However, the cash generation and balance sheet trajectories are deteriorating: cash and equivalents fell from $178.7M (Dec 2024) to $100.2M (Jun 2026) with no financing inflows in 2026, the company disclosed substantial doubt about its ability to continue as a going concern, and the SVB loan’s interest-only period ends September 30, 2026, triggering $11.7M in current maturities. Revenue is also declining as the Amgen upfront payment is nearly fully recognized (deferred revenue $0.6M remaining).

2. Red Flags

• Going concern qualification: Management concluded substantial doubt exists about the ability to continue as a going concern for twelve months from the Q2 2026 filing date; cash expected to fund operations only into Q2 2027 (10-Q 2026-06-30, Note 1).
• Cash depletion with no financing: Cash and equivalents declined $78.5M in the first half of 2026 (from $152.4M to $100.2M) while net cash from financing was only $0.1M, compared to $208.8M in full-year 2024 and $0 in Q1 2026 (10-K 2025-12-31, Cash Flows; 10-Q 2026-06-30, Cash Flows).
• Revenue cliff: Collaboration revenue fell 61% YTD (2026 $2.0M vs 2025 $5.2M) and deferred revenue shrank to $0.6M, indicating the $30M Amgen upfront is nearly fully recognized with no new agreements disclosed (10-Q 2026-06-30, Condensed Statements of Operations; Note 6).
• Debt acceleration trigger: The SVB loan’s interest-only period ends September 30, 2026 because the Company missed a required financial milestone by June 30, 2026, converting $11.7M to current portion and requiring monthly principal payments thereafter (10-Q 2026-06-30, Note 8).
• Accumulated deficit growth: Accumulated deficit reached $563.9M as of June 30, 2026, up from $504.9M at December 31, 2025 and $375.1M at December 31, 2024 (10-Q 2026-06-30, Condensed Balance Sheets).

3. Earnings Assessment (Income Statement)

Earnings Trajectory: Mixed

Annual results show slight deterioration: FY 2025 net loss widened to $129.8M from $127.5M in FY 2024, with total operating expenses rising 6.2% to $146.1M despite a 267% revenue increase to $10.3M (10-K 2025-12-31, Consolidated Statements of Operations). In contrast, quarterly and year-to-date comparisons show clear improvement: Q2 2026 net loss narrowed to $30.4M from $37.0M in Q2 2025, and YTD 2026 net loss narrowed to $59.0M from $71.1M, driven by a 23.1% reduction in total operating expenses (to $61.7M from $80.2M) following the November 2025 restructuring that cut headcount ~30% and paused the solid tumor program (10-Q 2026-06-30, Condensed Statements of Operations; MD&A). Revenue declined 61.5% YTD due to timing of Amgen research activities.

4. Cash Generation Assessment (Statement of Cash Flows)

Cash Trajectory: Deteriorating

Operating cash burn increased annually: net cash used in operations rose to $135.3M in FY 2025 from $110.8M in FY 2024 (10-K 2025-12-31, Cash Flows). However, YTD operating cash burn improved to $51.8M in H1 2026 from $70.9M in H1 2025, reflecting lower operating losses (10-Q 2026-06-30, Cash Flows). The critical deterioration is in total cash change: FY 2025 net cash decreased $26.3M versus a $45.3M increase in FY 2024 (no equity/debt raises in 2025), and H1 2026 net cash decreased $52.3M versus $9.3M in H1 2025 because financing provided only $0.1M (ESPP) versus $0.4M used in H1 2025 (10-K 2025-12-31, Cash Flows; 10-Q 2026-06-30, Cash Flows). Cash and equivalents fell to $100.2M at June 30, 2026 from $152.4M at December 31, 2025.

5. Balance Sheet Assessment

Balance Sheet Trajectory: Deteriorating

Liquidity and equity positions have contracted each quarter: cash and equivalents declined sequentially from $178.7M (Dec 2024) to $152.4M (Dec 2025) to $128.1M (Mar 2026) to $100.2M (Jun 2026) (10-K 2025-12-31, Balance Sheet; 10-Q 2026-03-31, Balance Sheet; 10-Q 2026-06-30, Balance Sheet). Total stockholders’ equity fell from $241.0M to $123.1M to $96.9M to $69.0M over the same periods. Total liabilities decreased modestly from $130.1M to $102.4M, but the composition shifted adversely: the SVB loan’s current portion appeared at $11.7M at June 30, 2026 (zero previously) as the interest-only period ends September 30, 2026 (10-Q 2026-06-30, Balance Sheet; Note 8). Marketable securities were fully liquidated by December 2025 ($111.4M at Dec 2024 to $0 at Dec 2025).

6. Data Gaps

• Q3 2025 and Q4 2025 standalone quarterly results (only annual FY 2025 and Q1/Q2 2025/2026 are provided)
• Q3 2026 and Q4 2026 quarterly results
• Full FY 2026 annual results
• Detailed marketable securities rollforward for FY 2025 (XBRL shows $111.4M at Dec 2024 and $0 at Dec 2025 but investing cash flow shows $109.4M net provided)
• Terms and probability assessment of Amgen milestone payments (>$500M potential) and royalty rates
• Specific financial milestone missed under SVB Loan Agreement (only described as "certain financial milestone")